Bepirovirsen hepatitis B results are the rare medical headline where the cautious version is still genuinely big news.
GSK says its investigational drug produced a 19 percent functional cure response in pooled Phase 3 B-Well trial data. The placebo plus standard-care group was 0 percent. In patients with lower baseline hepatitis B surface antigen levels, the response rate reached 26 percent.
What Functional Cure Means Here
This is not the same as saying the virus is erased from every cell. GSK defines functional cure as hepatitis B virus DNA and hepatitis B surface antigen being undetectable in blood for at least six months after stopping all treatment. In plain English, the disease appears controlled without ongoing medication.
That matters because chronic hepatitis B can mean long-term therapy. GSK says standard care typically delivers functional cure rates below 1 percent. The Phase 3 data were also published in the New England Journal of Medicine, which gives the results more weight than a standalone company announcement.
Do Not Call It Done Yet
The next phase is regulatory review. GSK says bepirovirsen is under priority review at the FDA. It is also being reviewed in Europe, Japan, and China. The company expects the first regulatory decisions in the third quarter of 2026.
That means patients should not treat this as available medical advice. It is a promising trial result, not a reason to start or stop treatment. Anyone with hepatitis B should talk to a clinician before changing care.
The study also gives researchers a clearer target. People with lower starting surface-antigen levels appeared more likely to respond. That could shape how doctors identify the first patients if the drug is approved.
For a disease that affects more than 240 million people worldwide, even a limited functional cure rate could become a major shift. The real test now is approval, access, and whether the benefit holds up outside the headline.